Latest Wet Amd Therapeutics News

Page 1 of 1

Opthea Advances Sozinibercept Trials with $131.9M Cash Buffer and R&D Boost

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Victor Sage

31 Jan 2025

Top